Lawrence T. Friedhoff MA, PhD, MD

Lawrence Friedhoff, MD, PhD has worked in pharmaceutical research and development for more than three decades. He has led and managed teams that developed and obtained approval for six drugs, including Aricept (donepezil), the most widely used drug for the treatment of Alzheimer's disease. He is the chief development officer at Axovant Sciences, Inc., a biopharmaceutical company focused on dementia solutions.

He is the author of New Drugs: An Insider's Guide to the FDA Approval Process for Scientists, Investors, and Patients and has authored and coauthored numerous articles for peer-reviewed publications. He holds an MD from New York University, a PhD in chemistry from Columbia University and is a fellow of the American College of Physicians.